Blood: Fibrinolytics Flashcards
Serine protease catalysed from its zymogen precursor
Plasmin from plasminogen catalysed by fibrinolytics
This lyses tye thrombi
Generalised lyrics state
With IV fibrinolytics
Goal of early fibrinolytics
Clot dissolution and reperfusion
When to give fibrinolytics
Give IV
Multiple venous emboli
Central DVT
Acute MI
Give IArterial
Peripheral Vascular Diseases
Adverse effect of fibrinolytics
Bleeding
Treat bleeding with
Tranexamic acid
Fresh plasma
Coagulation factors
Streptokinase
Protein synthesised From srmtrptococci
Combines with coactivator plasminogen to form enzymatic complex
Streptokinase
Systemic fibrinolytic
As streptokinase acts on plasmjnogen in both thrombus and plasma
Given IV
Added streptokinase adverse effects
Allergy
Fever
Urokinase
Human enzyme from urine of pregnant women
-synthesised by the kidney
Anistreplase
Combo of strepto and proactivator plasminogen
Tissue plasminogen activators- Alteplase and Reteplase
Recombinant DNA tech like
Recombinant like Andexanetalfa (for quasi factor 10a)
Selective activation of thrombus plasminogen for LOCAL fibrinolytic effect
Alteplase and reteplase - IV
No allergy with
Alte and reteplase
Reteplase has
Longer half life so given as bolus
Fibrinolytic inhibitors
Oral or IV aminocaproic acid and tranexamic acid
Indications for fibrinolytics
Bleeding from fibrinolytic therapy
Adjunctive in hemophilia
Post prostectomy bleeding
Rebleeding in intracranial Aneurysms
Intravascular thrombosis in fibrinolytic inhibitors
From inhibition of plasminogen activator
Management of thromboembolic diseases
Venous and arterial thromboembolism
Venous
DVT
DVT + pulmonary thrombolism
DVT
Initial therapy - anticoagulant for the first 5 - 10 days
LMWH and Fondaparinux referred over UFH
Combination therapy
Paranteral overlapping with oral (warfarin) for a minimum of 5 days to get to 2 -3×INR
Maintenance of DVT
For at least 3 months:
Oral anticoagulant; warfatjn with monitoring of INR or rivaroxaban or apixaban